Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
1.7.
2021

Cantargia AB today announced the submission of the clinical trial application for TRIFOUR, a phase Ib/II trial investigating nadunolimab (CAN04) combined with gemcitabine and carboplatin for treatment of triple negative breast cancer (TNBC). After an initial safety lead in, the study will include a randomized phase II part. This trial will be performed in Spain in collaboration with the Spanish Breast Cancer Group, GEICAM. Up to 120 patients may be included and the first patient is estimated to be enrolled in November 2021.

Tiedotteet
29.6.
2021

Cantargia AB today announced that the development of nadunolimab (CAN04) has been broadened following the submission of an application of a phase I/II clinical trial to evaluate combination with chemotherapy in three different forms of solid tumors. Thus, the development of CAN04 is expanded to biliary tract cancer (BTC) and colorectal cancer (CRC), and extended to new patient populations in non-small cell lung cancer (NSCLC). The study, called CESTAFOUR, will be conducted at approximately 20 clinical centres in Europe. The first patient is estimated to be enrolled in September 2021.

Tiedotteet
8.6.
2021

Cantargia AB today announce that the clinical trial application to investigate the antibody nadunolimab (CAN04) in combination with the FOLFIRINOX chemotherapy regimen for first line treatment of metastatic pancreatic cancer (PDAC), has been approved by the regulatory authority and the central ethics committee in France. The current estimate is to enroll the first patient in June 2021.

Muut analyysit
27.5.
2021

After Cantargia's CMD last week, the Q1 report offered few surprises. The increased operating loss versus our previous estimate was likely due to R&D investments during the quarter.

Tiedotteet
26.5.
2021
Cantargia's Annual General Meeting on 26 May 2021 resolved in accordance with the following:
  • That no dividend would be paid
  • To discharge the board members and the managing director from liability with respect to their management of the company for 2020.
  • That the board shall comprise eight board members without any deputy board members.
  • To re-elect the board members Magnus Persson, Patricia Delaite, Thoas Fioretos, Karin Leandersson, Anders Martin-Löf and Flavia Borellini and to re-elect Magnus Persson as the chairman of the board.
  • To elect Magn
Muut analyysit
26.5.
2021

Cantargia reported their Q1 this morning with an operating loss of SEK -73.2m, 45% more than we expected (SEK -50.5m) and up 83% from last year (SEK -39.9m).

Tiedotteet
26.5.
2021

Cantargia AB's ("Cantargia") interim report for first quarter 2021 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Tiedotteet
20.5.
2021

Cantargia AB today announced positive results from the ongoing CANFOUR trial investigating nadunolimab (CAN04) in combination with gemcitabine/nab-paclitaxel (Abraxane[®]) for first line treatment of patients with advanced pancreatic cancer (PDAC). The efficacy analysis included 33 patients. Overall, the efficacy compares favorably to historical control data.

Tiedotteet
10.5.
2021

Cantargia AB today presented new results on the antibody CAN10 at the annual meeting of the American Association of Immunologists (AAI), Virtual IMMUNOLOGY 2021. These data demonstrate that the interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN10 reduces inflammation and/or fibrosis in several disease models including myocarditis. CAN10, which blocks signaling of IL-1, IL-33 and IL-36, counteracted deterioration of the cardiac function more potently than blockade of IL-1 signaling only.

Tiedotteet
6.5.
2021

Cantargia AB today announced signing a Letter of Intent with the Spanish Breast Cancer Group (GEICAM) to perform a new clinical trial investigating the antibody nadunolimab (CAN04) in combination with carboplatin/gemcitabine for the treatment of patients with advanced triple negative breast cancer (TNBC). The trial will investigate the safety and efficacy of the combination in this difficult to treat breast cancer. The total number of patients is estimated to be up to 120 and includes a randomized part after initial safety lead in. The protocol is planned to be submitted during Q2 2021.

Cantargia